JP2007532649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532649A5 JP2007532649A5 JP2007508407A JP2007508407A JP2007532649A5 JP 2007532649 A5 JP2007532649 A5 JP 2007532649A5 JP 2007508407 A JP2007508407 A JP 2007508407A JP 2007508407 A JP2007508407 A JP 2007508407A JP 2007532649 A5 JP2007532649 A5 JP 2007532649A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl group
- compound
- medicament
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- -1 quinuclidine compound Chemical class 0.000 claims 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 claims 1
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 150000002978 peroxides Chemical class 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56264304P | 2004-04-15 | 2004-04-15 | |
| PCT/US2005/012028 WO2005108378A2 (en) | 2004-04-15 | 2005-04-12 | Use of (4-alkylpiperazinyl) (phenyl) methanones in the treatment of alzheimer’s disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007532649A JP2007532649A (ja) | 2007-11-15 |
| JP2007532649A5 true JP2007532649A5 (enExample) | 2008-05-29 |
Family
ID=35058789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007508407A Pending JP2007532649A (ja) | 2004-04-15 | 2005-04-12 | （４−アルキルピペラジニル）（フェニル）メタノン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090197891A1 (enExample) |
| EP (1) | EP1755605A2 (enExample) |
| JP (1) | JP2007532649A (enExample) |
| CN (1) | CN101022806A (enExample) |
| AU (1) | AU2005240991A1 (enExample) |
| CA (1) | CA2564068A1 (enExample) |
| WO (1) | WO2005108378A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| CA2628703C (en) | 2005-11-30 | 2019-10-29 | Abbott Laboratories | Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| CN104744591B (zh) | 2010-04-15 | 2022-09-27 | Abbvie德国有限责任两合公司 | β淀粉样蛋白结合蛋白 |
| WO2012024187A1 (en) | 2010-08-14 | 2012-02-23 | Abbott Laboratories | Amyloid-beta binding proteins |
| ES2919779T3 (es) | 2017-06-20 | 2022-07-28 | Imbria Pharmaceuticals Inc | Derivado de 1-[(2,3,4-trimetoxifenil)metil]-piperazina, composiciones del mismo y métodos para aumentar la eficiencia del metabolismo cardíaco |
| CN108329282B (zh) * | 2018-01-16 | 2022-01-07 | 新乡医学院 | 一种苯基哌嗪类衍生物及其制备方法和应用 |
| US12318382B2 (en) | 2018-10-17 | 2025-06-03 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
| WO2022246115A1 (en) * | 2021-05-19 | 2022-11-24 | Cornell University | Apt1 and apt2 inhibitors and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2304155A1 (de) * | 1973-01-29 | 1974-08-01 | Ichthyol Ges Cordes Hermanni & | N-acylierte substituierte piperazinbzw. homopiperazinderivate, sowie verfahren zu ihrer herstellung |
| US5693804A (en) * | 1994-11-17 | 1997-12-02 | Molecular Geriatrics Corporation | Substituted 1-aryl-3-piperazin-1'-yl propanones |
| DE19934433A1 (de) * | 1999-07-22 | 2001-01-25 | Merck Patent Gmbh | N-(Indolcarbonyl-)piperazinderivate |
| US20040034019A1 (en) * | 2002-08-08 | 2004-02-19 | Ronald Tomlinson | Piperazine and piperidine derivatives |
| GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| WO2004108666A2 (en) * | 2003-06-02 | 2004-12-16 | Samaritan Pharmaceuticals, Inc. | Neuroprotective benzoate and benzamide compounds |
-
2005
- 2005-04-12 AU AU2005240991A patent/AU2005240991A1/en not_active Abandoned
- 2005-04-12 JP JP2007508407A patent/JP2007532649A/ja active Pending
- 2005-04-12 US US10/599,952 patent/US20090197891A1/en not_active Abandoned
- 2005-04-12 WO PCT/US2005/012028 patent/WO2005108378A2/en not_active Ceased
- 2005-04-12 CA CA002564068A patent/CA2564068A1/en not_active Abandoned
- 2005-04-12 EP EP05776434A patent/EP1755605A2/en not_active Withdrawn
- 2005-04-12 CN CNA2005800194203A patent/CN101022806A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007532649A5 (enExample) | ||
| JP2003509349A5 (enExample) | ||
| JP2009536191A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2006502143A5 (enExample) | ||
| JP2009542613A5 (enExample) | ||
| RU2010107284A (ru) | Производные нафтиридина в качестве модуляторов калиевых каналов | |
| ES2759312T3 (es) | Compuestos de aminocarbonilcarbamato | |
| JP2003501474A5 (enExample) | ||
| JP2012505836A5 (enExample) | ||
| EP2592070A3 (en) | Tetrazole-substituted arylamides | |
| EP1537859A3 (en) | Azithromycin dosage forms with reduced side effects | |
| JP2009531404A5 (enExample) | ||
| JP2008539267A5 (enExample) | ||
| ES2698363T3 (es) | Composiciones de oxprenolol para tratar el cáncer | |
| JP2012505879A5 (enExample) | ||
| JP2014505017A5 (enExample) | ||
| JP2007502832A5 (enExample) | ||
| JP2014510782A5 (enExample) | ||
| JP2012505905A5 (enExample) | ||
| RU2009128970A (ru) | Производные изосорбидмононитрата для лечения кишечных заболеваний | |
| JP2002509858A5 (enExample) | ||
| JP2010510263A5 (enExample) | ||
| JP2006516643A5 (enExample) | ||
| RU2009145537A (ru) | Терапевтические соединения |